Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics said it has aligned with the FDA on the design of its NOV-ERA Phase 2b trial of ontunisertib for fibrostenosing Crohn’s disease, including a primary endpoint of endoscopic passability at Week 24. The randomized, double-blind study plans up to 320 adults and dosing begins in the second half of 2026.
How this was made
The 30-second read
Why it matters
FDA alignment on the NOV-ERA Phase 2b primary endpoint (endoscopic passability at Week 24 via SES-CD narrowing) and cleared IRB/Health Canada approval improve execution visibility and reduce regulatory design risk ahead of enrollment.
Market read
Traders may view this as a meaningful de-risking step (protocol/endpoint alignment and approvals) that sets up a clear catalyst window for future enrollment and later Week 24/52 readouts.
What to watch
The article provides no prior efficacy/safety datapoints for this specific endpoint, and the primary endpoint is imaging/endoscopic-based, which can be sensitive to site performance and patient selection.
Background
Fibrostenosing Crohn’s disease (FSCD) has large unmet need and no approved pharmacologic therapies; ontunisertib is a GI-restricted ALK5/TGF-β inhibitor in clinical development.
Ticker impact
Agomab announced FDA-aligned Phase 2b NOV-ERA study design for ontunisertib, with primary endpoint endoscopic passability at Week 24 and first dosing in 2H 2026.
Shares may see a modest positive reaction as the market prices lower regulatory risk and clearer path to later readouts, though near-term impact is limited until enrollment/results.
This is a primary, company-specific development milestone (protocol submitted/cleared, IRB/Health Canada approval, dosing window). However, it does not include efficacy/safety data, so upside is likely incremental rather than re-rating on fundamentals.
Market effects
Adds another ALK5/TGF-β pathway fibrosis program milestone in GI fibro-inflammation, potentially supporting sentiment toward similar clinical-stage biopharma fibrosis assets.
Regulatory submissions/approvals across U.S. and Health Canada plus CTA filings in EU/Asia Pacific broaden execution confidence for global trial operations.
Multiregion protocol progress can improve comparability of endpoints and accelerate future registrational discussions if results are positive.
Counterpoint
A well-defined Phase 2b design doesn’t de-risk the core question—whether ontunisertib can deliver endoscopic passability at Week 24; trial outcomes remain the main driver.
Key entities
- companyAgomab Therapeutics NV
Clinical-stage biopharmaceutical company advancing ontunisertib in FSCD; announced NOV-ERA Phase 2b study design and regulatory alignment.
- drugontunisertib (AGMB-129)
Investigational oral GI-restricted ALK5/TGF-β RI inhibitor; Phase 2b NOV-ERA trial design disclosed.
- clinical_trialNOV-ERA Phase 2b study
Randomized, double-blind, placebo-controlled dose-ranging trial; primary endpoint endoscopic passability at Week 24; first dosing targeted for 2H 2026.
- regulatorFDA
Aligned on key elements of the Phase 2b study design, including the primary endpoint.
